Ensign Peak Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19.7M | Hold |
487,310
| – | – | 0.03% | 321 |
|
|
2025
Q1 | $25M | Sell |
487,310
-82,746
| -15% | -$4.25M | 0.05% | 268 |
|
|
2024
Q4 | $31.6M | Sell |
570,056
-16,974
| -3% | -$940K | 0.06% | 246 |
|
|
2024
Q3 | $19.3M | Sell |
587,030
-7,295
| -1% | -$240K | 0.03% | 335 |
|
|
2024
Q2 | $16.2M | Sell |
594,325
-133,566
| -18% | -$3.63M | 0.03% | 349 |
|
|
2024
Q1 | $26.5M | Buy |
727,891
+290,000
| +66% | +$10.5M | 0.05% | 272 |
|
|
2023
Q4 | $8.87M | Hold |
437,891
| – | – | 0.02% | 467 |
|
|
2023
Q3 | $7.78M | Buy |
437,891
+195,440
| +81% | +$3.47M | 0.02% | 455 |
|
|
2023
Q2 | $4.38M | Hold |
242,451
| – | – | 0.01% | 623 |
|
|
2023
Q1 | $3.05M | Hold |
242,451
| – | – | 0.01% | 694 |
|
|
2022
Q4 | $3.55M | Hold |
242,451
| – | – | 0.01% | 648 |
|
|
2022
Q3 | $4.15M | Hold |
242,451
| – | – | 0.01% | 566 |
|
|
2022
Q2 | $3.54M | Hold |
242,451
| – | – | 0.01% | 620 |
|
|
2022
Q1 | $4.08M | Hold |
242,451
| – | – | 0.01% | 652 |
|
|
2021
Q4 | $5.46M | Buy |
242,451
+42,451
| +21% | +$955K | 0.01% | 641 |
|
|
2021
Q3 | $4.31M | Hold |
200,000
| – | – | 0.01% | 721 |
|
|
2021
Q2 | $5.8M | Hold |
200,000
| – | – | 0.01% | 600 |
|
|
2021
Q1 | $6.45M | Hold |
200,000
| – | – | 0.01% | 539 |
|
|
2020
Q4 | $8.27M | Buy |
+200,000
| New | +$8.27M | 0.02% | 469 |
|